Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 12/4/24 → 12/4/26 |
Funding
- Novocure GmbH: $30,483.00
24-GBM-16-NL (EF-41): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant with Maintenance Temozolomide and Placebo for the Tre
- Villano, PhD, John (PI)